Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive […]
The post Revive Therapeutics (RVV.C) incredible patent-portfolio explained appeared first on Equity.Guru.
Mydecine Innovations Group (MYCO.C) psilocybin work with NeuroPharm is a step towards creating a better worldJuly 16, 2020 War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason our civilization is advanced as it is. If it weren’t for the catalyst of hundreds of years of continuous war, including the prospect of mutually assured […]
Red Light Holland (TRIP.C) announced they have entered into a definitive agreement as part of their acquisition of Mera Life Sciences. Red Light and Mera have entered into an acquisition agreement that would see Red Light acquire 100% of issued and outstanding shares of Mera for a consideration of $2,450,000, which Red Light will pay […]
The post Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition appeared first on Equity.Guru.
Braxia Scientific (BRAX.C) filed their Q4 and full year-end results for the three and twelve month periods ending on March 31, 2021. At the end of March 2021, Braxia reported $11,395,899 in cash and $18,490,005 in assets, which is up significantly from March 2020, when they had $3,063,693 in cash and assets. That being said, […]
The post Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses appeared first on Equity.Guru.
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under […]
The post Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering appeared first on Equity.Guru.
Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and ManufacturingJuly 29, 2021
Filament Health (FH.NEO) announced today that it has been granted an amendment to its existing Health Canada Dealer’s License, bolstering the Company’s position at the forefront of natural psychedelic research and manufacturing. “This license amendment significantly increases the scope of our work with natural psychedelics…By studying untapped psychedelics in a scientific setting, we believe we […]